UPDATE 1-Sanofi's dual-action biotech asthma drug performs well in test

Nov 11 (Reuters) - An experimental biotech drug for moderate to severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting that its dual-action mechanism may be highly effective.